NASDAQ:ADXS - Advaxis Stock Price, Forecast & News

Advaxis trades on the NASDAQ under the ticker symbol "ADXS."

Advaxis, Inc. (NASDAQ:ADXS) released its earnings results on Friday, December, 20th. The biotechnology company reported ($0.15) EPS for the quarter. Advaxis had a negative return on equity of 40.98% and a negative net margin of 79.31%. View Advaxis' Earnings History.

Advaxis is scheduled to release their next quarterly earnings announcement on Tuesday, March 10th 2020. View Earnings Estimates for Advaxis.

1 Wall Street analysts have issued 12-month target prices for Advaxis' shares. Their forecasts range from $4.00 to $4.00. On average, they expect Advaxis' share price to reach $4.00 in the next twelve months. This suggests a possible upside of 310.0% from the stock's current price. View Analyst Price Targets for Advaxis.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Advaxis in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Advaxis.

Press coverage about ADXS stock has trended very positive this week, InfoTrie Sentiment reports. The research group rates the sentiment of press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Advaxis earned a coverage optimism score of 4.0 on InfoTrie's scale. They also gave news stories about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the stock's share price in the next few days. View News Stories for Advaxis.

Some companies that are related to Advaxis include Sol Gel Technologies (SLGL), Kala Pharmaceuticals (KALA), Aeglea Bio Therapeutics (AGLE), Arcturus Therapeutics (ARCT), LifeVantage (LFVN), Theratechnologies (THERF), Agile Therapeutics (AGRX), Arbutus Biopharma (ABUS), Cerecor (CERC), Affimed (AFMD), Theratechnologies (THTX), Abeona Therapeutics (ABEO), Kezar Life Sciences (KZR), Nature's Sunshine Products (NATR) and Athersys (ATHX).

Based on aggregate information from My MarketBeat watchlists, some companies that other Advaxis investors own include Inovio Pharmaceuticals (INO), Madrigal Pharmaceuticals (MDGL), Merck & Co., Inc. (MRK), Anavex Life Sciences (AVXL), Vistagen Therapeutics (VTGN), Celgene (CELG), Novavax (NVAX), Highpower International (HPJ), BIOLINERX LTD/S (BLRX) and Opko Health (OPK).

Advaxis' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (6.28%), Geode Capital Management LLC (0.75%) and Raymond James Financial Services Advisors Inc. (0.08%). Company insiders that own Advaxis stock include Robert Petit and Roni Appel. View Institutional Ownership Trends for Advaxis.

ADXS stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Geode Capital Management LLC and Raymond James Financial Services Advisors Inc.. View Insider Buying and Selling for Advaxis.

Shares of ADXS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ADXS stock can currently be purchased for approximately $0.98.

Advaxis has a market capitalization of $58.74 million and generates $20.88 million in revenue each year. The biotechnology company earns $-16,610,000.00 in net income (profit) each year or ($1.09) on an earnings per share basis. Advaxis employs 58 workers across the globe.View Additional Information About Advaxis.

The official website for Advaxis is http://www.advaxis.com/.

Advaxis' mailing address is 305 COLLEGE ROAD EAST, PRINCETON NJ, 08540. The biotechnology company can be reached via phone at 609-452-9813 or via email at [email protected]